6066 RESULTS
Sort By:
Amyloid Time: Because amyloid burden grows at a constant rate after having crossed a tipping point, scientists were able to predict when a person’s symptoms will begin, using only his or her age and one PET scan.
In Lewy body dementia brain tissue, CD4+ T cells loitered near synuclein aggregates and dopaminergic neurons. In vitro, T cells reacted to α-synuclein fragments by spewing the pro-inflammatory cytokine interleukin 17A.
A combination of retinoic acid and the cholesterol drug gemfibrozil prompted astrocytes to ingest and degrade Aβ. Mice treated this way had fewer amyloid plaques and performed better on cognitive tests.
The widely used psychiatric drug lithium, and other agents that inhibit glycogen synthase kinase-3 (GSK3), have been mentioned as possible Alzheimer's disease therapies for some time, primarily because GSK3 is one of several kinases known to phosphorylate tau...
A mixed bag of epidemiologic studies alternatively hold up and knock down the promise that...
As the first of a suite of PET β amyloid imaging agents stands poised to receive a ruling from the FDA, seven scientists are questioning the validity of this technology...
A paper out today in Cell proposes a novel role for presenilins in calcium signaling...
For the first time, researchers have identified duplications of the amyloid precursor protein (APP) gene locus...
Of all clinical trials reported at the ICAD, one targeting the protein tau was the <em>therapy du jour</em>...
In the future, could Alzheimer disease treatments come as an ointment, or a skin patch?...
After a tough year, during which believers in immunotherapy for Alzheimer’s disease have had to fend off vociferous criticism, the news now appears to pick up...
On Saturday, 27 October, in Los Angeles, an unusual conference marked a paradigm shift in the Alzheimer disease movement...
Flurizan has floundered in an 18-month Phase 3 clinical trial in patients with mild Alzheimer disease...
Alzheimer's disease researchers expressed sadness this week at the sudden death of Larry Sparks...
A new study finds that the cancer drug imatinib does not lower Aβ in humans, casting doubt on a previously described relationship between imatinib, γ-secretase activating protein (GSAP), and Aβ.
No filters selected
